TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02812251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
Study: NCT01966198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt test
Description: The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
Study: NCT02742532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal oxytocin 40 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal saline solution
Study: NCT01335412

Intervention type: BIOLOGICAL
Intervention: Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Description: 2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
Study: NCT00366860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Soy bread
Study: NCT00743587

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oral, 1 x 20mg controlled-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Oral, 2 x 50mg immediate release capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Oral, 1 x 500mg enteric-coated
Study: NCT02705040

Intervention type: OTHER
Intervention: Normal
Description: bone mineral density T\>=-1.0

Intervention type: OTHER
Intervention: Normal
Description: bone mineral density T\>=-1.0

Intervention type: OTHER
Intervention: Osteopenia
Description: bone mineral density -1.0\>T\>=-2.5

Intervention type: OTHER
Intervention: Osteopenia
Description: bone mineral density -1.0\>T\>=-2.5

Intervention type: OTHER
Intervention: Osteoporosis
Description: bone mineral density T\<-2.5

Intervention type: OTHER
Intervention: Osteoporosis
Description: bone mineral density T\<-2.5
Study: NCT02450773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 40 mg furosemide on postpartum day 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride
Description: 20 meq potassium chloride on postpartum day 1-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo #1
Description: Placebo (for furosemide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo #2
Description: Placebo (for KCl)
Study: NCT03242603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2 in combination with NK cells
Description: Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
Study: NCT01132638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Pantoprazole
Description: 1 capsule daily, 40 mg, orally, 30 minutes before breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Esomeprazole
Description: 1 capsule daily, 40 mg, orally, 30 minutes before breakfast
Study: NCT00823550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg QD
Study: NCT02142920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: Single 89 mg Dose via 30 minute IV infusion
Study: NCT01722916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Study: NCT00856934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keratinocyte suspension
Description: Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard dressings
Description: Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard dressings
Description: Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard dressings
Description: Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
Study: NCT02520999

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)
Description: Blood pass through infusion set without external pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)
Description: Blood pass through infusion set without external pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg
Description: Blood pass through infusion set under external pressure (150mmHg)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg
Description: Blood pass through infusion set under external pressure (150mmHg)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg
Description: Blood pass through infusion set under external pressure (200mmHg)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg
Description: Blood pass through infusion set under external pressure (200mmHg)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg
Description: Blood pass through infusion set under external pressure (250mmHg)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg
Description: Blood pass through infusion set under external pressure (250mmHg)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg
Description: Blood pass through infusion set under external pressure (300mmHg)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg
Description: Blood pass through infusion set under external pressure (300mmHg)
Study: NCT03518658

Intervention type: OTHER
Intervention: Evaluation Group
Description: Patient receiving exposure to the MyCareLink Heart App during device pairing

Intervention type: OTHER
Intervention: Control Group (Historical)
Description: Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C). The patients' data will be extracted from Medtronic de-identified CareLink™ database.
Study: NCT04203927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: SGLT-2 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: SGLT-2 inhibitor
Study: NCT04842994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IONM tube
Description: The standardized technique of IONM-RLNs (bilaterally) will be used, including indirect vagal response evaluation at the beginning and also at the end of surgery according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group (INMSG) (Randolph GW, Dralle H. 2011).
Study: NCT02812251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study: NCT04267159

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute cardioversion
Description: Acute restoration of sinus rhythm by medical or electrical cardioversion in the emergency department

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed cardioversion
Description: Delayed restoration of sinus rhythm by medical or electrical cardioversion in the out-patient clinic
Study: NCT02638051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modulated Electro-Hyperthermia (mEHT)
Description: MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCM Herbal Decoction (Shi Pi)
Description: Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPCI (CDDP+5FU)
Description: Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
Study: NCT01454414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permethrin Impregnated Uniforms
Description: Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
Study: NCT00033306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT03277716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWA
Description: MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MWA system
Description: MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
Study: NCT04451668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT218
Description: once nightly sodium oxybate extended release
Study: NCT03157726

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral plasmakinetic enucleation of prostate
Description: Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral resection of prostate
Description: Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH.
Study: NCT04108663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Effect of tDCS on cognitive control task performance
Description: Added verum or sham tDCS while working on a cognitive control task.
Study: NCT00750919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmirtazapine
Study: NCT02527915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health eConsults
Description: Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Providers in primary care clinics will deliver care as usual to their patients.
Study: NCT03139864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: controlled physical activity
Description: Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: controlled physical activity
Description: Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
Study: NCT04650334

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collaborative Care
Description: Health services intervention to implement a team based model of care for perinatal depression.
Study: NCT03350204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscectomy
Description: This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helathy control comparison
Description: This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.
Study: NCT01440569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: 150 mg tablet administered orally with food once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: 800 mg (2 x 400 mg tablets) administered orally with food once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
Study: NCT04209439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 ml %0.25 bupivacaine
Description: Ultrasound-guided erector spinae plane block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-trometamol
Description: 50 mg Dexketoprofen-trometamol intravenous
Study: NCT04328610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique
Description: Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
Study: NCT01120132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA high dose
Description: Solution of Cyclosporine (high dose) administered during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA high dose
Description: Solution of Cyclosporine (high dose) administered during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA low dose
Description: Solution of Cyclosporine (low dose) administered during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA low dose
Description: Solution of Cyclosporine (low dose) administered during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA
Description: Suspension of Prednisolone Acetate administered during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA
Description: Suspension of Prednisolone Acetate administered during 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PA
Description: Suspension of Prednisolone Acetate administered during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution administered during 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution administered during 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution administered during 28 days
Study: NCT04002778

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle aspiration

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fine needle aspiration

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid on-site evaluation
Study: NCT01399476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Myotomy
Description: Patients will receive the surgical procedure described in the summary (POEM).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Myotomy for treatment of achalasia
Description: Surgical procedure
Study: NCT00840736

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Description: Laparoscopic adjustable gastric banding

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical banded gastroplasty
Description: vertical banded gastroplasty